These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 31047311)

  • 21. Long-term Effects of Intravitreal 0.19 mg Fluocinolone Acetonide Implant on Progression and Regression of Diabetic Retinopathy.
    Wykoff CC; Chakravarthy U; Campochiaro PA; Bailey C; Green K; Cunha-Vaz J
    Ophthalmology; 2017 Apr; 124(4):440-449. PubMed ID: 28081945
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema.
    Campochiaro PA; Brown DM; Pearson A; Ciulla T; Boyer D; Holz FG; Tolentino M; Gupta A; Duarte L; Madreperla S; Gonder J; Kapik B; Billman K; Kane FE;
    Ophthalmology; 2011 Apr; 118(4):626-635.e2. PubMed ID: 21459216
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Spontaneous Dissociation of Fluocinolone Acetonide Sustained Release Implant (Retisert) with Dislocation into the Anterior Chamber.
    Chang PY; Kresch Z; Samson CM; Gentile RC
    Ocul Immunol Inflamm; 2015; 23(6):454-7. PubMed ID: 24724735
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combined Ahmed Glaucoma Valve Placement, Intravitreal Fluocinolone Acetonide Implantation and Cataract Extraction for Chronic Uveitis.
    Chang IT; Gupta D; Slabaugh MA; Vemulakonda GA; Chen PP
    J Glaucoma; 2016 Oct; 25(10):842-846. PubMed ID: 27300641
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combined fluocinolone acetonide intraocular delivery system insertion, phacoemulsification, and intraocular lens implantation for severe uveitis.
    Chieh JJ; Carlson AN; Jaffe GJ
    Am J Ophthalmol; 2008 Oct; 146(4):589-594. PubMed ID: 18639220
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cytomegalovirus retinitis after fluocinolone acetonide (Retisert) implant.
    Ufret-Vincenty RL; Singh RP; Lowder CY; Kaiser PK
    Am J Ophthalmol; 2007 Feb; 143(2):334-5. PubMed ID: 17258523
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Management of fluocinolone implant dissociation during implant exchange.
    Yeh S; Cebulla CM; Witherspoon SR; Emerson GG; Emerson MV; Suhler EB; Albini TA; Flaxel CJ
    Arch Ophthalmol; 2009 Sep; 127(9):1218-21. PubMed ID: 19752436
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of Macular Edema after Pars Plana Vitrectomy for Idiopathic Epiretinal Membrane Using Intravitreal Dexamethasone Implant: Long-Term Outcomes.
    Chatziralli I; Dimitriou E; Theodossiadis G; Chatzirallis A; Kazantzis D; Theodossiadis P
    Ophthalmologica; 2019; 242(1):16-21. PubMed ID: 30889589
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intravitreal triamcinolone acetonide versus pars plana vitrectomy for pseudophakic cystoid macular edema.
    Sevim MS; Sanisoglu H; Turkyilmaz K
    Curr Eye Res; 2012 Dec; 37(12):1165-70. PubMed ID: 22928501
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Diabetic macular edema outcomes in eyes treated with fluocinolone acetonide 0.2 µg/d intravitreal implant: real-world UK experience.
    El-Ghrably I; Steel DHW; Habib M; Vaideanu-Collins D; Manvikar S; Hillier RJ
    Eur J Ophthalmol; 2017 May; 27(3):357-362. PubMed ID: 28165610
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of diabetic macular edema with sustained-release glucocorticoids: intravitreal triamcinolone acetonide, dexamethasone implant, and fluocinolone acetonide implant.
    Ciulla TA; Harris A; McIntyre N; Jonescu-Cuypers C
    Expert Opin Pharmacother; 2014 May; 15(7):953-9. PubMed ID: 24661081
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pars plana vitrectomy with intravitreal triamcinolone: effect on uveitic cystoid macular oedema and treatment limitations.
    Gutfleisch M; Spital G; Mingels A; Pauleikhoff D; Lommatzsch A; Heiligenhaus A
    Br J Ophthalmol; 2007 Mar; 91(3):345-8. PubMed ID: 17005547
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intravitreal Dexamethasone Implant for the Treatment of Postoperative Macular Edema.
    Klamann A; Böttcher K; Ackermann P; Geerling G; Schargus M; Guthoff R
    Ophthalmologica; 2016; 236(4):181-185. PubMed ID: 27915343
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dexamethasone intravitreal implant for treatment of uveitic persistent cystoid macular edema in vitrectomized patients.
    Adán A; Pelegrín L; Rey A; Llorenç V; Mesquida M; Molins B; Ríos J; Keller J
    Retina; 2013; 33(7):1435-40. PubMed ID: 23514796
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Introduction.
    Puliafito CA
    Ophthalmic Surg Lasers Imaging Retina; 2016 Apr; 47(4 Suppl):S4. PubMed ID: 27096288
    [No Abstract]   [Full Text] [Related]  

  • 36. Long-term follow-up results of a pilot trial of a fluocinolone acetonide implant to treat posterior uveitis.
    Jaffe GJ; McCallum RM; Branchaud B; Skalak C; Butuner Z; Ashton P
    Ophthalmology; 2005 Jul; 112(7):1192-8. PubMed ID: 15921758
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intravitreal therapeutic agents in noninfectious uveitic macular edema.
    Shah KK; Majumder PD; Biswas J
    Indian J Ophthalmol; 2018 Aug; 66(8):1060-1073. PubMed ID: 30038143
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intravitreal fluocinolone acetonide (Iluvien) for treatment of refractory diabetic macular oedema in vitrectomised eyes.
    Kumar A; Alfahad Q; Mitra A; Elsherbiny S; Lip PL
    Eye (Lond); 2016 May; 30(5):763-4. PubMed ID: 26795414
    [No Abstract]   [Full Text] [Related]  

  • 39. Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis: thirty-four-week results of a multicenter randomized clinical study.
    Jaffe GJ; Martin D; Callanan D; Pearson PA; Levy B; Comstock T;
    Ophthalmology; 2006 Jun; 113(6):1020-7. PubMed ID: 16690128
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Intraoperative photo of fluocinolone acetonide and dexamethasone implants].
    Matonti F; Conrath J; Devin F; Morin BR; Morel C
    J Fr Ophtalmol; 2021 Sep; 44(7):1100-1101. PubMed ID: 34016475
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.